Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from T...

by Kerwin EM, Murray L, Niu X, Dembek C
Published 2020-09-01

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

by Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A
Published 2018-11-01

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment

by Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP
Published 2019-05-01

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS

by Stephenson JJ, Dembek C, Caldwell-Tarr A, Conto RM, Paullin M, Kerwin EM
Published 2020-07-01